The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022: Featured Updates to the NCCN Guidelines
Abstract
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7625 · Cited by 1,841
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Self-citationRecent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Self-citationGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670
Self-citationInvasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Self-citationPignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Freyer, G., Geay, J.-F., Touzet, S., Provencal, J., Weber, B., Jacquin, J.-P., Ganem, G., Tubiana-Mathieu, N., Gisserot, O., & Pujade-Lauraine, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi368 · Cited by 339
New insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 317
Salama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 308
Self-citationRecurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gershenson, D. M., Sun, C. C., Bodurka, D., Coleman, R. L., Lu, K. H., Sood, A. K., Deavers, M., Malpica, A. L., & Kavanagh, J. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.001 · Cited by 291
Self-citationClinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Self-citationHormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., & Sun, C. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0632 · Cited by 279
Self-citationPrat, J., D'Angelo, E., & Espinosa, I. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 275
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., Minasian, L. M., & Unger, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2346 · Cited by 246
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02175-9 · Cited by 232
Self-citationBRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Wong, K.-K., Tsang, Y. T. M., Deavers, M. T., Mok, S. C., Zu, Z., Sun, C., Malpica, A., Wolf, J. K., Lu, K. H., & Gershenson, D. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100212 · Cited by 220
Self-citationLow‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 218
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Gershenson, D. M., Sun, C. C., Iyer, R. B., Malpica, A. L., Kavanagh, J. J., Bodurka, D. C., Schmeler, K., & Deavers, M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.037 · Cited by 210
Self-citationPatterns and Progress in Ovarian Cancer Over 14 Years
Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., Whittemore, A. S., Berek, J. S., & Osann, K. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000231680.58221.a7 · Cited by 163
Reclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study
Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., et al. (2012) · Cancer · doi:10.1002/cncr.26618 · Cited by 160
Self-citationMonk, B. J., Grisham, R. N., Banerjee, S. N., Kalbacher, E., Mirza, M. R., Romero, I., Vuylsteke, P., Coleman, R. L., Hilpert, F., Oza, A. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01164 · Cited by 158
Self-citationCheasley, D. A., Nigam, A., Zethoven, M., Hunter, S. M., Etemadmoghadam, D., Semple, T. J., Allan, P. E., Carey, M. S., Fernández, M. L., Dawson, A., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5545 · Cited by 145
Falandry, C., Weber, B. E., Savoye, A.-M., Tinquaut, F., Trédan, O., Sevin, E., Stefani, L., Savinelli, F., Atlassi, M., Salvat, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt360 · Cited by 124
Park, H. K., Ruterbusch, J. J., & Coté, M. L. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0290 · Cited by 114
Fader, A. N., Bergstrom, J., Jernigan, A. M., Tanner, E. J., Roche, K. L., Stone, R. L., Levinson, K. L., Ricci, S., Wethingon, S., Wang, T., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.127 · Cited by 102
Self-citationStewart, S. L., Harewood, R., Matz, M., Rim, S. H., Sabatino, S. A., Ward, K. C., & Weir, H. K. (2017) · Cancer · doi:10.1002/cncr.31027 · Cited by 84
Trédan, O., Geay, J.-F., Touzet, S., Delva, R., Weber, B. E., Crétin, J., Provençal, J., Martin, J., Stefani, L., Pujade-Lauraine, É., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl400 · Cited by 82
von Gruenigen, V. E., Huang, H. Q., Beumer, J. H., Lankes, H. A., Tew, W. P., Herzog, T. J., Hurria, A., Mannel, R. S., Rizack, T., Landrum, L. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.033 · Cited by 81
Gourley, C., Farley, J. H., Provencher, D. M., Pignata, S., Mileshkin, L., Harter, P., Maenpaa, J. U., Kim, J., Pujade-Lauraine, É., Glasspool, R. M., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000257 · Cited by 76
Self-citationPignata, S., Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., Vivo, R. D., Ferrandina, G., Gallo, C., et al. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.005 · Cited by 75
Fairfield, K. M., Murray, K. A., Lucas, F. L., Wierman, H. R., Earle, C. C., Trimble, E. L., Small, L., & Warren, J. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1552 · Cited by 67
Gershenson, D. M., Sun, C. C., Westin, S. N., Eyada, M., Cobb, L. P., Nathan, L. C., Sood, A. K., Malpica, A. L., Hillman, R. T., & Wong, K. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.11.019 · Cited by 65
Self-citationCobb, L. P., Sun, C. C., Iyer, R. B., Nick, A. M., Fleming, N. D., Westin, S. N., Sood, A. K., Wong, K., Silva, E. G., & Gershenson, D. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.498 · Cited by 61
Self-citationTinquaut, F., Freyer, G., Chauvin, F., Gane, N., Pujade-Lauraine, É., & Falandry, C. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.018 · Cited by 33
Falandry, C., Savoye, A.-M., Stefani, L., Tinquaut, F., Lorusso, D., Herrstedt, J., Bourbouloux, E., Floquet, A., Brachet, P. E., Zannetti, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5508 · Cited by 32
Cited by
Matulonis, U. A., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., Colombo, N., Van Gorp, T., Konner, J. A., Marin, M. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01900 · Cited by 395
Clinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
Treatment Approaches for Platinum-Resistant Ovarian Cancer
St Laurent, J., & Liu, J. F. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01771 · Cited by 88
Self-citation
Metadata
- Authors
- Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Chitiyo, V. C., Cristea, M., DeRosa, M., Eisenhauer, E. L., Gershenson, D. M., Gray, H. J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G. E., Leath III, C. A., Leiserowitz, G., Liu, J., Martin, L., Matei, D., McHale, M., McLean, K., Miller, D. S., Percac-Lima, S., Remmenga, S. W., Schorge, J., Stewart, D., Thaker, P. H., Vargas, R., Hendrickson, A. W., Werner, T. L., Zsiros, E., Dwyer, M. A., & Hang, L.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2022-09
- Volume
- 20
- Issue
- 9
- Pages
- 972-980
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4294982904
- Cited by
- 401
- References
- 37
- FWCI
- 59.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.